Stock Taper
SPRC
SCISPARC LTD.
NASDAQ
$6.58
▼ DOWN 0.60% (-0.04)

KEY STATISTICS

Market Cap$380.58 K
52w High$80.10
52w Low$2.98
Dividend Yield
Frequency
P/E-0.04
Volume84.13K
Shares Out.57.84K

COMPANY

LEADERSHIP

Oz Adler
CHIEF EXECUTIVE
Oz Adler

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 30, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
3

SPLIT RECORD

DATETYPERATIO
2026-03-04Reverse1:9
2025-07-03Reverse1:21
2023-09-28Reverse1:26

PRICE

$6.58 ▼ DOWN 0.60% (−$0.04)
OVERLAYS
$6.50$6.60$6.709:51 AM10:52 AM11:54 AM12:55 PM1:56 PM2:58 PM3:59 PM6.58

About SciSparc Ltd.

https://scisparc.com ↗

SciSparc Ltd. is a Tel Aviv-based clinical-stage pharma company developing cannabinoid-based drugs for conditions like Tourette’s, sleep apnea, Alzheimer’s, pain, autism, and epilepsy, with multiple clinical trials and partnerships.

INDUSTRY

Biotechnology

A PRODUCT SCISPARC LTD. IS KNOWN FOR

MUSE™ system
MUSE™ system

The MUSE™ system is a single-use endoscopic device for minimally invasive transoral fundoplication to treat GERD, marking SciSparc’s entry into the $billion medical device market with commercialization planned after acquiring its IP in January 2026.

COMPETITORS

ETFS HOLDING THIS STOCK

ETFS HOLDING
6
LISTED HERE
1
RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED
0.00%
HOLDERS
1
TOP 1 OF 1 · RANKED BY POSITION SIZE
Ahrens Investment Partners LLC
1 sh · $0

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book5
Overall Score2

INSIDER TRADES

DIRECTOR
Weiss Amitay
· 6 shares
2022-01-03
DIRECTOR
Shrem Itschak
· 6 shares
2022-01-03
DIRECTOR
Sidi Liat
· 1 shares
2022-01-03
DIRECTOR
Vider Lior
· —
2026-03-18

SECTORS PEERS

PEERPRICE
INDP$1.14COMPARE
JSPR$0.70COMPARE
ARTL$0.66COMPARE
ONCO$0.61COMPARE
PTIX$0.98COMPARE
SLXN$0.36COMPARE
LIPO$0.00COMPARE
SCNI$2.51COMPARE